Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 8 hours ago
- 1 min read
20/04/2026
Nektar Therapeutics announced results from Phase 2b study for rezpegaldesleukin in severe-to-very severe AA (Ref)
Nektar Therapeutics announced topline results from its Phase 2b REZOLVE-AA/ NCT06340360 study, which evaluated rezpegaldesleukin (IL-2 pathway agonist) for the treatment of patients with severe-to-very-severe alopecia areata (AA).
29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatment.
Favorable safety profile with twice-monthly dosing was maintained throughout 52 weeks, consistent with previously reported results.
Results supported advancement of rezpegaldesleukin into late-stage development in AA.
Nektar planned to submit the REZOLVE-AA results for presentation at a medical conference in 2026.
Biogen entered into agreement with TJ Biopharma for felzartamab in the Greater China Region (Ref)
Biogen and TJ Biopharma announced that the companies had entered into a definitive agreement under which Biogen agreed to acquire TJ Bio’s exclusive rights to felzartamab (CD38-directed antibody) in the Greater China Region.
With this agreement, Biogen owned exclusive worldwide development and commercial rights to felzartamab, consolidating global rights under one owner.
Under the terms of the agreement, TJ Bio was set to receive a $100 million upfront payment and was eligible to receive up to $750 million in potential commercial and sales based milestone payments, for a total potential consideration of up to $850 million, plus mid-single-digit to low-double-digit % of royalties on potential net sales in the Greater China Region.
